Vertex Pharmaceuticals (VRTX -3.4%) slips after SA contributor Edward Vranic highlights a recent...


Vertex Pharmaceuticals (VRTX -3.4%) slips after SA contributor Edward Vranic highlights a recent insider transaction by the company's CFO. Form 4 filings seem to show a large block of shares transacted on April 19, the day the stock rose more than 60% on positive Phase 2 trial data (I, II, III). Earlier this week, S&P equity research raised their price target to $100 from $60, adding to a slew of positive analyst coverage the stock has received over the past week. Cramer's take: "Don't sell your Vertex, [it] has a breakout drug right now."

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs